Effect of zoledronic acid on bone density and markers of bone turnover in a community clinic.
OBJECTIVE
This study aims to document the efficacy of zoledronic acid by comparing bone densities and markers of bone turnover, in patients with osteoporosis.


METHODS
Bone mineral density (BMD) and urinary N-telopeptide, a marker of bone turnover, were compared before and after treatment with intravenous zoledronic acid.


RESULTS
52 participants had atleast two doses of zoledronic acid over 36 months. Significant increases in BMD were found in the spine (t=4.38, P<0.01) and decrease in bone turnover marker N-telopeptide (t=3.30, P=0.002). Small but significant correlations were determined between prior steroid use and change in BMD in the spine (r=0.35, P<0.05), and family history of osteoporosis and change in BMD in the right femur (r=0.38, P<0.05).


CONCLUSIONS
Annual infusions of zoledronic acid for at least two years, revealed a significant increase in bone density at the spine and a decrease in urinary N-telopeptide in patients treated at our center.
Endocrinology and Bone Health Center, The Hospital of Central Connecticut, New Britain, USA.
Ria
R
Lim
Susan
S
Zailskas
Tashauna U
TU
Goldsby
Carrie
C
Lukens
Rostislav
R
Muravev
Latha
L
Dulipsingh
D015502:Absorptiometry, Photon; D000368:Aged; D015415:Biomarkers / Q000378:metabolism*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D024042:Collagen Type I / Q000652:urine; D004164:Diphosphonates / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006764:Hospitals, Community; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000652:urine; D012189:Retrospective Studies; D000077211:Zoledronic Acid
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D007093:Imidazoles; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000077211:Zoledronic Acid